 RALEIGH, NC ACCESSWIRE May 7, 2020 9 Meters Biopharma, Inc NASDAQ:NMTR, today announced that it has closed the merger with Naia Rare Diseases, a company developing a proprietary long-acting glucagon-like peptide-1 GLP-1 receptor agonist for the treatment of Short Bowel Syndrome SBS and other rare gastrointestinal diseases. Currently, NM-002 is the only therapy being developed in SBS that directly addresses increased bowel motility. 